Status:
RECRUITING
TGRX-1942 Chinese Phase I for Advanced Solid Tumor And/or Relapsed/Refractory Hematologic Malignancies
Lead Sponsor:
Shenzhen TargetRx, Inc.
Collaborating Sponsors:
Sir Run Run Shaw Hospital
Conditions:
Non Small Cell Lung Cancer
Advanced Solid Tumor
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
A phase I study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of TGRX-1942 in patients with advanced solid tumor and/or relapsed or refractory hematological malignanc...
Detailed Description
This study is designed as a three-part study, with dose escalation, dose expansion and indication expansion phases. Patients with advanced solid tumors will be initially enrolled to the study. Other i...
Eligibility Criteria
Inclusion
- For dose escalation phase, patient is diagnosed with advanced/metastatic solid tumor who had failed standard therapies and does not have available effective treatment, or who relapsed from prior treatments
- ECOG score of equals to or lower than 1
- Life expectancy of at least 3 months
- Adequate systemic and organ functions, including hematologic, hepatic and kidney functions
- Willing to provide available tumor biopsy sample or reports, or willing to undergo tumor biopsy examination, and willing to partake whole blood sampling for evaluations
- For female of child-bearing potential, willing to undergo plasma pregnancy test 28 days before first dose and have negative results
- Male and Female of child-bearing potential must agree to take effective contraceptive measures during the entire treatment period and for 2 months after the end of treatment
- Understand and willing to sign informed concent; willing and able to complete the visiting schedule and other tasks as required for the study
Exclusion
- Allergic to any of the ingredient of the investigational drug
- History of other primary malignancies
- Have adverse/toxic effects from previous treatment that has not recovered to CTCAE 5.0 \<= Grade 1
- Received other anti-tumor treatments (i.e., chemotherapy, biologics, immunotherapy, targeted therapy, etc.) 28 days before first dose, or radiation therapy 14 days before first dose
- Used drugs known to significantly affect P450 metabolism 2 weeks before first dose
- Participated in other clinical trials and used other investigational agents 28 days before first dose
- Received major surgeries or had traumatic injuries 28 days before first dose
- Need to use concomitant drugs that could cause QTc elongation or induce Torsades de Pointes
- History or presence of other medical conditions, such as HIV/HBV/HCV positive; received anticoagulation treatment; coagulation dysfunction; major or clinically significant cardiovascular disease; pneumonia; clinically significant gastrointestinal abnormalities that could affect drug absorption; uncontrollable hypertension; ulcer in abdomen, intestine, stomach, trachea or esophagus; uncontrolled seizure or have other central nervous system diseases, poorly managed diabetes; long QT syndrome; uncontrolled active infections; uncontrolled pericardial or abdominal effusion; adrenaline malfunction; thyroid dysfunction; severe unhealed wound, ulcer or bone fractures; Toxic epidermal necrolysis; Stevens-Johnson syndrome
- Have symptomatic or uncontrolled primary or metastatic central nervous system tumor or Leptomeninges tumor, or untreated diseases that cause compressions to spinal cords
- For female patients: in pregnancy or breast-feeding periods
- Presence of any condition or history that could affect study results or participation to the study in the judgement of the investigator
- Used immunosuppressant drugs within14 days before first dose
- Received vaccine injection within 30 days of Cycle 1 Day 1
Key Trial Info
Start Date :
July 8 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2027
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT06484816
Start Date
July 8 2024
End Date
June 1 2027
Last Update
February 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China, 310009